Cargando…

Novel Plasminogen Activator Inhibitor-1 Inhibitors Prevent Diabetic Kidney Injury in a Mouse Model

Diabetic nephropathy is the leading cause of end-stage renal disease worldwide, but no effective therapeutic strategy is available. Because plasminogen activator inhibitor-1 (PAI-1) is increasingly recognized as a key factor in extracellular matrix (ECM) accumulation in diabetic nephropathy, this st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeong, Bo Yeong, Uddin, Md Jamal, Park, Jong Hee, Lee, Jung Hwa, Lee, Hi Bahl, Miyata, Toshio, Ha, Hunjoo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892642/ https://www.ncbi.nlm.nih.gov/pubmed/27258009 http://dx.doi.org/10.1371/journal.pone.0157012

Ejemplares similares

TM5441, a plasminogen activator inhibitor-1 inhibitor, protects against high fat diet-induced non-alcoholic fatty liver disease
por: Lee, Seon Myeong, et al.
Publicado: (2017)

CO-Releasing Molecule-2 Prevents Acute Kidney Injury through Suppression of ROS-Fyn-ER Stress Signaling in Mouse Model
por: Uddin, Md Jamal, et al.
Publicado: (2021)

Mechanisms of Epithelial-Mesenchymal Transition of Peritoneal Mesothelial Cells During Peritoneal Dialysis
por: Lee, Hi Bahl, et al.
Publicado: (2007)

Inhibition of Src Family Kinases Ameliorates LPS-Induced Acute Kidney Injury and Mitochondrial Dysfunction in Mice
por: Pak, Eun Seon, et al.
Publicado: (2020)

Carbon monoxide releasing molecule-2 protects mice against acute kidney injury through inhibition of ER stress
por: Uddin, Md Jamal, et al.
Publicado: (2018)

Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity
por: Placencio, Veronica R., et al.
Publicado: (2015)

A novel pan-Nox inhibitor, APX-115, protects kidney injury in streptozotocin-induced diabetic mice: possible role of peroxisomal and mitochondrial biogenesis
por: Kwon, Guideock, et al.
Publicado: (2017)

Fyn Kinase: A Potential Therapeutic Target in Acute Kidney Injury
por: Uddin, Md Jamal, et al.
Publicado: (2020)

PGC‐1α, a potential therapeutic target against kidney aging
por: Lee, Gayoung, et al.
Publicado: (2019)

Pharmacotherapy against Oxidative Stress in Chronic Kidney Disease: Promising Small Molecule Natural Products Targeting Nrf2-HO-1 Signaling
por: Uddin, Md Jamal, et al.
Publicado: (2021)

Inhibition of Plasminogen Activator Inhibitor 1 Attenuates Hepatic Steatosis but Does Not Prevent Progressive Nonalcoholic Steatohepatitis in Mice
por: Henkel, Anne S., et al.
Publicado: (2018)

Prospective Pharmacological Potential of Resveratrol in Delaying Kidney Aging
por: Uddin, Md Jamal, et al.
Publicado: (2021)

Kidney protective potential of lactoferrin: pharmacological insights and therapeutic advances
por: Zahan, Md. Sarwar, et al.
Publicado: (2022)

Novel Role of Endogenous Catalase in Macrophage Polarization in Adipose Tissue
por: Park, Ye Seul, et al.
Publicado: (2016)

Plasminogen activator inhibitor type 1 regulates microglial motility and phagocytic activity
por: Jeon, Hyejin, et al.
Publicado: (2012)

Protective Effects of Black Cumin (Nigella sativa) and Its Bioactive Constituent, Thymoquinone against Kidney Injury: An Aspect on Pharmacological Insights
por: Hannan, Md. Abdul, et al.
Publicado: (2021)

Inhibition of plasminogen activator inhibitor-1 attenuates against intestinal fibrosis in mice
por: Imai, Jin, et al.
Publicado: (2020)

Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 Levels in Patients with Acute Paraquat Intoxication
por: Seok, Su-Jin, et al.
Publicado: (2011)

Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor‐1 inhibitor TM5614 combined with a tyrosine kinase inhibitor
por: Takahashi, Naoto, et al.
Publicado: (2022)

Effects of Korean Red Ginseng extract on tissue plasminogen activator and plasminogen activator inhibitor-1 expression in cultured rat primary astrocytes
por: Ko, Hyun Myung, et al.
Publicado: (2013)

Association between Plasma Levels of Plasminogen Activator Inhibitor-1 and Colorectal Neoplasms
por: Kim, Eun Ran, et al.
Publicado: (2013)

Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells
por: Yahata, Takashi, et al.
Publicado: (2020)

Catalase Deficiency Accelerates Diabetic Renal Injury Through Peroxisomal Dysfunction
por: Hwang, Inah, et al.
Publicado: (2012)

Plasminogen activator inhibitor-1 (PAI-1) expression in endometriosis
por: Alotaibi, Fahad T., et al.
Publicado: (2019)

The effects of residual platelets in plasma on plasminogen activator inhibitor-1 and plasminogen activator inhibitor-1-related assays
por: Pieters, Marlien, et al.
Publicado: (2017)

Relationship between tissue plasminogen activator, plasminogen activator inhibitor and CT image in chronic subdural hematoma.
por: Lim, D. J., et al.
Publicado: (1995)

Localization of Urokinase‐type Plasminogen Activator, Plasminogen Activator Inhibitor‐1, 2 and Plasminogen in Colon Cancer
por: Naitoh, Hiroyuki, et al.
Publicado: (1995)

Plasminogen Activator Inhibitor-1 Antagonist TM5484 Attenuates Demyelination and Axonal Degeneration in a Mice Model of Multiple Sclerosis
por: Pelisch, Nicolas, et al.
Publicado: (2015)

The role of plasminogen activator inhibitor-2 in pneumococcal meningitis
por: Teske, Nina C., et al.
Publicado: (2022)

Retraction: The effects of residual platelets in plasma on plasminogen activator inhibitor-1 and plasminogen activator inhibitor-1-related assays
Publicado: (2018)

Vitamin D Deficiency is Associated With Increased Plasminogen Activator Inhibitor 1/Plasminogen Activator Inhibitor 2 Ratio in Pregnancy
por: Andersen, Matilde Kanstrup, et al.
Publicado: (2023)

Functional Stability of Plasminogen Activator Inhibitor-1
por: Yasar Yildiz, Songul, et al.
Publicado: (2014)

Activators and inhibitors of the plasminogen system in Alzheimer’s disease
por: Barker, Rachel, et al.
Publicado: (2012)

Novel oral plasminogen activator inhibitor-1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats
por: Noguchi, Ryuichi, et al.
Publicado: (2020)

Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency
por: Saes, Joline L., et al.
Publicado: (2019)

Editorial: The role of oxidative stress and systemic inflammation in diabetes and chronic kidney disease
por: Chanda, Dipanjan, et al.
Publicado: (2023)

Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1
por: Gong, Lihu, et al.
Publicado: (2016)

Role of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in psychological stress and depression
por: Tsai, Shih-Jen
Publicado: (2017)

Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients
por: Zuo, Yu, et al.
Publicado: (2021)

Tissue plasminogen activator and plasminogen activator inhibitor type 1 gene polymorphism in patients with gastric ulcer complicated with bleeding.
por: Kim, Hong-Soo, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_4su28h002jj6i9gmi9pnq3bagt